We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

78 hedge funds and large institutions have $249M invested in Relmada Therapeutics in 2025 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,400% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 1

3,304% more call options, than puts

Call options by funds: $1.94M | Put options by funds: $57K

1,504% more capital invested

Capital invested by funds: $15.5M → $249M (+$234M)

175% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 8

77% more funds holding

Funds holding: 44 → 78 (+34)

47.09% more ownership

Funds ownership: 23.32% → 70.41% (+47%)

Holders
78
Holders Change
+34
Holders Change %
+77.27%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
35
Increased
22
Reduced
8
Closed
1
Calls
$1.94M
Puts
$57K
Net Calls
+$1.88M
Net Calls Change
+$1.6M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$24.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$14.3M
3
Marshall Wace
Marshall Wace
United Kingdom
+$9.78M
4
O
OrbiMed
New York
+$8.75M
5
Ameriprise
Ameriprise
Minnesota
+$6.43M

Top Sellers

Rank Fund Capital Flow
1
AI
AdvisorShares Investments
Maryland
-$281K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$187K
3
Simplex Trading
Simplex Trading
Illinois
-$115K
4
RC
RBF Capital
California
-$77.9K
5
UBS Group
UBS Group
Switzerland
-$61.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Parsons Capital Management
Rhode Island
$1.27M +$334K +99,664 +61%
PAP
27
Persistent Asset Partners
Hong Kong
$1.12M +$774K +231,123 New
Deutsche Bank
28
Deutsche Bank
Germany
$1.09M – – –
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$905K +$628K +187,377 New
Renaissance Technologies
30
Renaissance Technologies
New York
$894K +$51.3K +15,300 +9%
Northern Trust
31
Northern Trust
Illinois
$799K +$357K +106,430 +180%
EI
32
EAM Investors
California
$785K +$545K +162,552 New
Two Sigma Advisers
33
Two Sigma Advisers
New York
$783K +$413K +123,400 +318%
Qube Research & Technologies (QRT)
34
Qube Research & Technologies (QRT)
United Kingdom
$751K +$521K +155,529 New
SFCM
35
Seven Fleet Capital Management
California
$744K +$516K +154,109 New
Goldman Sachs
36
Goldman Sachs
New York
$700K +$486K +145,000 New
RC
37
RBF Capital
California
$676K -$77.9K -23,261 -14%
Squarepoint
38
Squarepoint
New York
$668K +$463K +138,233 New
MOS
39
MGO One Seven
Ohio
$483K – – –
SEI Investments
40
SEI Investments
Pennsylvania
$478K +$332K +98,965 New
ECM
41
ExodusPoint Capital Management
New York
$333K +$231K +68,883 New
OAC
42
OMERS Administration Corp
Ontario, Canada
$318K +$221K +65,900 New
Morgan Stanley
43
Morgan Stanley
New York
$301K +$205K +61,318 +5,902%
Barclays
44
Barclays
United Kingdom
$290K +$168K +50,000 +500%
LP
45
LMR Partners
United Kingdom
$269K – – –
QC
46
Quadrature Capital
United Kingdom
$258K +$179K +53,444 New
Charles Schwab
47
Charles Schwab
California
$256K +$178K +53,081 New
AW
48
Apricus Wealth
South Carolina
$229K – – –
PFCS
49
Pale Fire Capital SE
Czech Republic
$215K +$149K +44,550 New
UBS Group
50
UBS Group
Switzerland
$200K -$61.4K -18,317 -31%
1
2
3 4

RLMD Hedge Fund Activity: Q4 2025 in Review

78 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2025, worth a combined $249M — up 1,504% from $15.5M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new RLMD positions and 1 closed out — a net gain of 34 holders — while 22 added to existing stakes and 8 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $24.4M. The largest seller was AdvisorShares Investments, cutting an estimated $281K.

  • 78 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2025, up from 44 in Q3 2025.
  • Funds reported $249M of Relmada Therapeutics stock for Q4 2025, up 1,504% quarter-over-quarter.
  • 35 funds opened new Relmada Therapeutics positions in Q4 2025 and 1 closed out, a net change of +34 holders.
  • The largest Relmada Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $24.4M added.
  • The largest Relmada Therapeutics seller in Q4 2025 was AdvisorShares Investments, an estimated $281K sold.

Based on aggregated 13F filings for Q4 2025.